1、 Vaccines and immunization for monkeypox Interim guidance 16 November 2022 Vaccines and immunization for monkeypox:Interim guidance ii Contents Executive Summary.1 Introduction.2 Changes from earlier version.2 Methods.2 Background.2 General goal and principles for the use of vaccines against monkeyp

2、ox.3 Summary of the evidence.3 Vaccine performance.3 Vaccine safety.4 Recommendations.6 Recommendation 1:Primary preventive(pre-exposure)vaccination(PPV).6 Recommendation 2:Post-exposure preventive vaccination(PEPV).6 Recommendation 3:Choice of vaccine and vaccination for special populations.7 Immun

3、ocompromised persons,including people living with HIV.7 Pregnancy.7 Breastfeeding women.8 Infants and children.8 Vaccination in previously smallpox-vaccinated individuals.9 Recommendation 4:Vaccination in the case of limited supply.9 Prioritization.9 Implementation considerations.10 Dose sparing opt

4、ions.10 Post-exposure prevention vaccination considerations.10 Research needs.12 Table of updates.13 Contributors.14 References.15 Funding.15 Vaccines and immunization for monkeypox:Interim guidance 1 Executive Summary The overarching goal of the global response to monkeypox is to stop the multi-cou

5、ntry outbreak by interrupting human-to-human transmission,to protect vulnerable groups at risk of severe monkeypox disease and to minimize zoonotic transmission of monkeypox virus.Judicious use of vaccines can support this response.This interim guidance provides WHO recommendations on use of vaccine

6、s for monkeypox.This version of the guidance has been endorsed by the WHO Strategic Advisory Group of Experts on Immunization(SAGE)in October 2022.General Monkeypox is an infectious disease caused by the monkeypox virus.This double-stranded DNA virus is a member of the Orthopoxvirus genus in the Pox